Cancer

Mecial Events

Contact us to enquire about advertising your events.

Editor
Editor
Editor
Editor

How ‘sleeper cell’ cancer stem cells are maintained in chronic myelogenous leukaemia

Most patients with chronic myelogenous leukaemia can be treated with tyrosine kinase inhibitors. These drugs are highly effective and lead to deep remission and prolonged survival. Yet quiescent leukaemic stem cells persist in these patients, and they therefore must continue inhibitor treatment to maintain remission.

Continue reading
Editor
Editor
Editor
Editor

Discovery may lead to precision-based strategy for triple negative breast cancer

According to the paper now available online, TP53 is the most frequently mutated gene in triple negative breast cancer, meaning it is fuelling the growth of this aggressive form of breast cancer. However, the problem with trying to target mutated TP53, specifically, is that it is not a druggable target, because of its potential toxicity – or ability to kill – nearby healthy cells.

Continue reading
Editor
Editor
Editor
Editor

Exploration of Innovations in Cancer Care in the Middle East: The Economist Events’ War on Cancer Middle East 2019

With a view to exploring cancer care access and innovations in the Middle East and addressing the regional issues hampering progress, The Economist Events will host War on Cancer Middle East on March 12th, 2019 at Rixos, Jumeirah Beach Residence, The Walk, Dubai.

Continue reading
Editor
Editor
Editor
Editor

Cancer comparison across species highlights new drug targets

Cancer genes in mucosal melanoma, a rare and poorly understood subtype of melanoma have been compared in humans, dogs and horses for the first time by scientists. Researchers sequenced the genomes of the same cancer across different species to identify key cancer genes.

Continue reading
Editor
Editor
Editor
Editor

Improving the body’s ability to fight cancer and intruders

A team of scientists have now developed two new methods for rapidly determining T cell targets. The work was done in the laboratory of David Baltimore, Robert Andrews Millikan Professor of Biology and president emeritus.

Continue reading
Editor
Editor
Editor
Editor

Nanomachines are taught to fight cancer

Scientists have proposed new DNA-based nanomachines that can be used for gene therapy of cancer. This new invention can greatly contribute to making the treatment of oncological diseases more effective and selective.

Continue reading
Editor
Editor
Editor
Editor

Aspirin to prevent colon cancer is under-utilised in high-risk patients

Colorectal cancer is the third most common cause of cancer deaths in the United States and advanced colorectal polyps are a major risk factor.
The U.S. Preventive Services Task Force (USPSTF) concluded that aspirin reduces the risk of colorectal cancer by 40 percent as well as recurrence of advanced polyps.

Continue reading
Editor
Editor
Editor
Editor

Researchers develop human cell-based model to study small cell lung cancer

Researchers have used human embryonic stem cells to create a new model system that allows them to study the initiation and progression of small cell lung cancer (SCLC).

Continue reading
Editor
Editor
Editor
Editor

Combination treatment, diabetes drug and immunotherapy, may help to fight breast cancer

MYC, a gene with high cancer-initiating potential, is overexpressed in over 40% of breast cancers.
While MYC programs breast cancer cells to build more macromolecules (anabolic metabolism), it also creates a metabolic vulnerability by making them more sensitive to a type of cell death known as apoptosis. Research Director Juha Klefstrom, PhD, University of Helsinki, Finland, has worked for a long time to exploit this apoptosis-sensitising effect of MYC in the battle against the cancer.

Continue reading
Editor
Editor
Editor
Editor

A new toolkit for studying how ‘PARP’ activity boosts cancers

A new method developed by scientists is likely to speed the study of an important biological process called ADP-ribosylation.ADP-ribosylation occurs at high levels in some cancers, and drugs called PARP (ADP-ribose polymerase) inhibitors, which block ADP-ribosylation, comprise one of the most promising new classes of cancer therapy.

Continue reading

Subscribe to our mailing list

 

 

Overlay